Oral antibiotic for Crohn’s induces remission in phase 3 study

Data from a phase 3 study centered on RHB-104 showed positive safety and efficacy results for the treatment of Crohn’s disease.
The manufacturer, RedHill Biopharma, said the drug was superior to placebo in achieving remission at 26 weeks, according to a press release.
“The robust results of this study demonstrate that RHB-104 could become a leading therapeutic option in Crohn’s disease and bring hope to patients worldwide,” Ira Kalfus, MD, medical director for RedHill said in the release. “The availability of antibiotic therapy for treating Crohn’s disease

Source link

Related posts

Several significant cholangiocarcinoma risk factors identified


Video of the Week: Dr. Uzma Siddiqui on the Natural History of Pancreatic Cysts–What Becomes of Them?


Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy